SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

QNT is drawing attention for a sharp, volatile rally and repeated attempts to break through resistance, with traders debating whether pullbacks are buying opportunities or signs of further downside. Bulls point to limited supply and anticipated institutional use of Quants network, while skeptics question how much that adoption would translate into demand for the token.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Reports that OpenAIs latest Ultrafast model runs on Nvidia GPUs have raised concerns about Cerebras key customer relationship, while staged IPO share unlocks and insider selling add pressure. Bulls cite Sam Altmans reassurance of a close partnership and Cerebras AI-inference opportunity, leaving traders divided over whether the selloff reflects lasting business risk or temporary uncertainty and share supply.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the Trump administrations Iran conflict, military escalation and elevated fuel costs, alongside criticism of the economy and speculation about the midterms. Sentiment toward DJT is largely bearish, with traders calling the stock overvalued or prone to pump-and-dump moves, though a few expect a rebound.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is under pressure after Kodiaks Zenkuda wet-AMD results raised competitive concerns; bears see a higher bar for AXPAXLI, while bulls argue the trials are not directly comparable and point to AXPAXLIs durability results and planned NDA filing as reasons for optimism.

Pump.fun

PUMP.fun is drawing attention amid volatile price moves and renewed rebound and breakout chatter; bullish traders cite the platforms revenue and token buybacks as supportive, while skeptics warn of selloffs and question the momentum.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

A weaker-than-expected jobs report eased expectations for further Fed tightening and pulled Treasury yields lower, prompting a relief bounce in rate-sensitive small caps. Traders remain divided on whether IWMs rebound near its 200-day average marks a turn or is temporary, given its recent underperformance and continued exposure to elevated rates.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Traders are reacting to a favorable natural-gas storage report and expectations that hot weather will support power demand, fueling hopes for a rebound in gas futures. The discussion remains divided, with bulls citing tighter storage while skeptics point to seasonal demand weakness, strong production, and BOILs futures-roll and leverage-related decay risks.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The G7s coordinated release of emergency oil and diesel stocks, alongside Trump ruling out a U.S. diesel export ban, is weighing on USO as traders assess whether added supply can ease energy-market pressure. The community is split: bears view the release as a reason for further weakness, while oil bulls argue it is a temporary fix amid ongoing Iran-related disruption and tight refined-product supplies.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings steep slide to multi-year lows is fueling debate over whether Kalshi and Polymarket are taking share and whether investment in DKeX will weigh on margins amid legal and regulatory uncertainty. Bears see intensifying competition as a threat, while bulls point to rising DKeX volume and sportsbook activity as evidence the business can hold up.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs reported consideration of a Texas fab campus is drawing attention as a potential expansion of U.S. chip capacity amid demand from major AI customers. Traders are also highlighting bullish call activity and momentum toward recent highs, though some are questioning whether the rally will hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.read more...

INCY or TECH: Which Is the Better Value Stock Right Now?

INCY vs. TECH: Which Stock Is the Better Value Option?

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss

Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary MiniMed appoints Sheila Denton as General Counsel & Corporate SecretaryPR NewswireNORTHRIDGE, Calif., Sept. 28, 2026 NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes...

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Equity

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.


Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older...

INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill

The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.


Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incytes Inflammation and Autoimmunity Portfolio

Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at...

FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week 

Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.


Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Bullish Sentiment

Up more than 5%

Flat to up 5%

Flat to down 5%

Down more than 5%

What&#39;s your expected total return for the S&amp;P 500 ($SPY) in Q4? 

Drop your reasoning in the comments.

Stocktwits

What's your expected total return for the S&P 500 (

) in Q4? 

Drop your reasoning in the comments.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$3.16	--	--	N/A
Q2 '26	$2.20	$3.09	40.72%	BEAT
Q1 '26	$1.32	$1.81	37.56%	BEAT
Q4 '25	$1.91	$1.80	-5.53%	MISSED
Q3 '25	$1.58	$2.26	42.69%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

INCY Earnings

Upcoming Earnings: Q3 '26

Historical Earnings